Clinical Trial

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Study acronym: PASIPHY
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 22, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2023-06-23; most recent amendment 2025-09-15.
Status change: Recruiting → Active, Not Recruiting 2025-09-15
Status change: Not Yet Recruiting → Recruiting 2024-01-10
Trial Details
NCT Number NCT05928390
Lead Sponsor RECORDATI GROUP
Conditions Post-Bariatric Hypoglycemia
Enrollment 93 participants
Start Date 2024-01-04
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-22